2026-04-17T16:15:47Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1732582025-12-05T11:56:00Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Gensthaler, Lisa author Joura, Elmar A. author Alemany i Vilches, Laia author Horvat, Reinhard author Sanjosé Llongueras, Silvia de author Pils, Sophie author 2021-01-20T17:30:13Z 2021-01-20T17:30:13Z 2020-03-01 2020-12-21T13:16:45Z Purpose To evaluate HPV and p16(ink4a) status as prognostic factors in patients with invasive vulvar cancer. Methods Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16(ink4a) status were evaluated in the context of a global multicenter trial. Logistic regression models were performed to identify the impact of p16(ink4a) positivity. Results 135 patients were included in the analysis. 32 (23.7%) showed a p16(ink4a) expression of over 25%. Disease-free and disease-specific survival was longer in p16(ink4a) positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, p = 0.016). In multivariate analysis, p16(ink4a) positivity was an independent parameter for DFS (p = 0.025, HR: 2.120 (1.100-4.085)), but not for DSS (p = 0.926, HR: 1.029 (0.558-1.901), in contrast to age and tumor stage. Conclusions Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16(ink4a) positive invasive vulvar cancer. Papil·lomavirus Càncer ginecològic Pronòstic mèdic Papillomaviruses Gynecologic cancer Prognosis The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study